MD Anderson Unveils 7 Cancer Studies, Highlighting Lung Biomarkers and Drug-Resistance Targets
Updated
Updated · Newswise · Aug 14
MD Anderson Unveils 7 Cancer Studies, Highlighting Lung Biomarkers and Drug-Resistance Targets
3 articles · Updated · Newswise · Aug 14
Summary
Seven new studies from UT MD Anderson spotlighted biomarkers, immune-cell signaling and tumor-environment targets that could sharpen cancer treatment selection and overcome resistance.
Nature data from the Phase 3 CheckMate 77T trial showed ctDNA clearance before surgery and pathologic complete response best predicted benefit from perioperative immunotherapy in resectable non-small cell lung cancer.
Cancer Cell research found a small population of immature NK cells in donor cord blood can derail CAR NK therapies by redirecting immune cells away from tumors, suggesting those cells should be removed during manufacturing.
Preclinical studies also pointed to new ways to improve treatment response: reshaping the gut microbiome roughly doubled circulation time for nanoparticle chemotherapy, while blocking an acidic-tumor signaling pathway restored PARP inhibitor sensitivity in ovarian cancer.
Other findings linked dysfunctional macrophage signaling to aggressive skin cancer in immunosuppressed patients, identified immune cells tied to recurrent arthritis after checkpoint inhibitors, and traced shared neuroimmune pathways in ketamine and psychedelic antidepressant responses.